Argent BioPharma has entered into a binding agreement to acquire the core operating assets and intellectual property (IP) of AusCann Group Holdings.
The deal, expected to complete in Q3 2025, includes AusCann’s interests in self-emulsifying hard-shell capsule Neuvis, CannPal Animal Therapeutics and WA-based European firm ECC Pharm.
Argent said the move strengthens its clinical pipeline and European commercial infrastructure, aligns with its plans for a dual listing in the US and enhances its IP-driven revenue model.
Earlier this year, the two firms announced a heads of agreement under which AusCann would licence Argent’s CannEpil drug and dossier for non-epilepsy conditions, while Argent would gain access to Neuvis, along with its pharmacokinetic and pharmacodynamic data.
The development was the first to emerge from AusCann since it was delisted from the Australian Securities Exchange in 2024.
The latest deal comprises AusCann’s 100% ownership of Neuvis and related IP, the firm’s 48% shareholding in CannPal and its 19.99% shareholding in ECC Pharm.
Under the agreement, Argent will issue AusCann 25,000,000 ordinary shares, valued at US$15 million (based on a deemed price per share of US$0.60), subject to shareholder approval.
Argent said the acquisition marks “a significant milestone in the company’s strategy to build a fully integrated, IP-led pharmaceutical platform with a global footprint”.
It added: “[Argent] will secure strategic interests in the Neuvis patented drug-delivery technology, gain access to a validated FDA-facing pre-clinical data package supporting CannEpil advancement, and benefit from scalable EU-GMP manufacturing and commercial infrastructure – each directly synergistic with Argent’s lead products CannEpil and CimetrA.
“The acquisition materially advances Argent BioPharma toward meeting the key financial and qualitative criteria for the planned US national listing.”
Once the deal is completed, AusCann executive director Andrew Chapman will join the Argent board.
Argent managing director and CEO, Roby Zomer, said: “This transaction brings together clinically validated IP, EU commercial infrastructure, and manufacturing scale under one platform.
“It positions Argent to expand globally while strengthening our core pipeline.”
Chapman added: “I know these assets well – and I’ve seen first-hand the value they unlock. From IP to revenue to regulatory readiness, this is a strategic acquisition that accelerates Argent’s pathway to a successful dual national listing in the US.”